denifanstat + Placebo
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
MASLD
Conditions
MASLD, MASH, NASH, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
Trial Timeline
Mar 1, 2025 → Jun 1, 2027
NCT ID
NCT06692283About denifanstat + Placebo
denifanstat + Placebo is a phase 3 stage product being developed by Sagimet Biosciences for MASLD. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06692283. Target conditions include MASLD, MASH, NASH.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06692283 | Phase 3 | Withdrawn |
| NCT06594523 | Phase 3 | Withdrawn |
Competing Products
1 competing product in MASLD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TVB-2640 25 mg (US) + TVB-2640 50 mg (US) + Placebo (US) + TVB-2640 50 mg (China) + Placebo (China) + TVB-2640 75 mg (US) | Sagimet Biosciences | Phase 2 | 44 |